Gold injections in rheumatoid arthritis are associated with a relatively high rate of side effects. It is our experience that some patients show a considerable therapeutic response to gold at the very moment of skin eruption. Colleagues with whom we shared this observation have had similar experiences. Publications on this topic are few as most reports describe therapeutic or side effects of gold without analysing their mutual interrelationships.
31 patients who developed skin eruption entered a concomitant clinical and laboratory remission. The remission satisfied the American Rheumatism Association preliminary criteria and was accompanied by a significant decrease of mean erythrocyte sedimentation rate from 43 (SD 13) to 25 (11) mm/h. Disease was exacerbated in 23 patients after three to 60 months. Eight patients are in remission at present, five to 68 months after gold treatment was discontinued. In contrast, no remission was noticed among the 19 patients with nephropathy or stomatitis.
Gold injections in rheumatoid arthritis are associated with a relatively high rate of side effects. It is our experience that some patients show a considerable therapeutic response to gold at the very moment of skin eruption. Colleagues with whom we shared this observation have had similar experiences. Publications on this topic are few as most reports describe therapeutic or side effects of gold without analysing their mutual interrelationships.
The report of the Empire Rheumatism Council' is the only study we could find that examined the relation between the toxic effects of gold and improvement. This work, however, found a better overall outcome in patients without toxicity, without analysing the various side effects separately.
We report a striking and previously undescribed association between skin eruption and remission induced by gold. Student's t test was used for statistical analysis.
Results
Patients were divided into three groups according to the type of gold toxicity: group A-31 patients with skin rashes, four of them with concomitant stomatitis; group B-10 patients with gold induced proteinuria; group C-nine patients with aphthous stomatitis without skin eruption. Table 1 summarises the characteristics of the patients. There were no significant differences among the groups with respect to age, sex, disease duration, the presence of rheumatoid factor, and sicca symptoms. Table 2 reports the clinical outcome and laboratory results at the time of the discontinuation of gold. All 31 patients who developed gold induced skin rash (group A) entered a concomitant clinical remission accompanied by a significant fall of erythrocyte sedimentation rate. The duration of remission varied greatly among the patients. Exacerbation occurred after an average of 12 months (range 3-60 months). Eight patients are in remission at present, five to 68 months after skin rash occurred. In contrast, none of the patients who suffered from proteinuria (n= 10), stomatitis (n=9), or thrombocytopenia (n=2, data not shown) had a clinical remission or a significant fall of erythrocyte sedimentation rate. Skin and mucosal lesions occurred earlier than gold induced nephropathy (p<0.05). Eosinophilia (range 0-62.1x1l9/l) preceding gold toxicity was noticed in four patients with skin eruption, but in none of the 19 patients of groups B and C.
Treatment of the skin rash required prednisone (dose range 10-20 mg/day) in four patients for a period of one to four weeks. Five patients received a single injection of corticotrophin. One patient who was receiving prednisone 10 mg/day before the start of gold treatment continued with the same regimen at the time of skin eruption and during the following remission.
During the remission eight patients did not require any drugs, 10 patients used analgesics sporadically, while only 13/31 patients required nonsteroidal anti-inflammatory drugs.
A history of allergy to drugs other than gold was present in five of the 31 patients of group A, in none of the patients who developed gold nephrotoxicity, and in one patient with stomatitis.
Discussion
When designing the present study we expected to discover a few patients in whom rash and response to gold coincided. On collecting the data we were surprised by the complete overlap between the two phenomena. All 31 patients who stopped gold thioglucose because of skin rash presented concomitant remissions of their disease, lasting five to 68 months and accompanied by a fall of erythrocyte sedimentation rate. In contrast, none of the patients with other gold induced side effects presented a similar response.
Although gold is the classical second line drug in rheumatoid arthritis, many facets of its activity remain obscure. The efficacy of gold was reported by the Empire Rheumatism Council in 1961,3 and by subsequent studies.4-7 Gold induced toxicity, most commonly mucocutaneous, has also been extensively reported.3 6 8 No means of predicting the beneficial outcome of gold treatment exists, though HLA-DR2 has generally been found to be associated with a better prognosis.9 Side effects have been associated with histocompatibility markers; renal and bone marrow toxicity were found to be related to HLA-B8 and DR3. 1"1'2 A association between mucocutaneous side effects and HLA-B35 has been reported by our group. 13 14 The correlation between toxicity and benefit of gold has not been previously described. 
